Triamcinolone as an adjunct to the combination of anti-VEGF for the management of diabetic macular edema

AIM: To assess the efficacy of intravitreal triamcinolone (IVTA) as an adjunct to the combination of anti-vascular endothelial growth factor (VEGF) for the management of diabetic macular edema (DME). METHODS: A total of 51 patients with visual disabilities causing by DME from two sites were retrospe...

Full description

Bibliographic Details
Main Authors: Ying-Ying Yu, Yong Cheng, Li-Bin Chang, Hui-Ka Xia, Xiao-Xin Li
Format: Article
Language:English
Published: Press of International Journal of Ophthalmology (IJO PRESS) 2021-06-01
Series:International Journal of Ophthalmology
Subjects:
Online Access:http://ies.ijo.cn/en_publish/2021/6/20210612.pdf
id doaj-a0ac03b3090f43b8916bbb5c7e45153d
record_format Article
spelling doaj-a0ac03b3090f43b8916bbb5c7e45153d2021-05-25T01:23:52ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982021-06-0114686987410.18240/ijo.2021.06.1220210612Triamcinolone as an adjunct to the combination of anti-VEGF for the management of diabetic macular edemaYing-Ying Yu0Yong Cheng1Li-Bin Chang2Hui-Ka Xia3Xiao-Xin Li4Xiao-Xin Li. Department of Ophthalmology & Clinical Centre of Optometry, Peking University People's Hospital, 11 Xizhimen South Street, Xicheng District, Beijing 100044, China. drlixiaoxin@163.comDepartment of Ophthalmology, Peking University People's Hospital, Eye diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing 100044, ChinaDepartment of Ophthalmology, Beijing Jingmei Group General Hospital, Beijing 102300, ChinaDepartment of Ophthalmology, Peking University People's Hospital, Eye diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing 100044, China; Department of Ophthalmology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, ChinaDepartment of Ophthalmology, Peking University People's Hospital, Eye diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing 100044, China; Xiamen Eye Center of Xiamen University, Xiamen 361003, Fujian Province, ChinaAIM: To assess the efficacy of intravitreal triamcinolone (IVTA) as an adjunct to the combination of anti-vascular endothelial growth factor (VEGF) for the management of diabetic macular edema (DME). METHODS: A total of 51 patients with visual disabilities causing by DME from two sites were retrospectively collected and assigned to two groups according to the therapeutic method: intravitreal conbercept (IVC) combined with focal laser (24 eyes) and IVC combined with focal laser and IVTA (27 eyes). Best-corrected visual acuity (BCVA), the required number of IVCs, central retinal thickness (CRT), the mean costs of treatment burden and safety were compared over 12mo. RESULTS: From baseline to month 1 through month 12, IVC combined with focal laser and IVTA improved the mean average change in BCVA superior to IVC combined with focal laser (+5.20 vs +2.71 letters). At month 12, 20.83% of the IVC combined with focal laser and 37.04% of IVC combined with focal laser and IVTA arms gained more than 10 BCVA letters. During the period, the mean CRT decreased significantly in the IVC combined with focal laser and IVTA arm (-245.9 μm) compared to the IVC combined with focal laser arm (-98.45 μm). The average of 6.45 and 1.25 conbercept injections performed in the IVC combined with focal laser and IVC combined with focal laser and IVTA arms, respectively. The mean cost of treatment burden for 12mo was $6247.44±4069.18 in the IVC combined with focal laser arm and $1679.19±542.73 in the IVC combined with focal laser and IVTA arm, with a statistically significant difference. Apart from occasional minor subconjunctival hemorrhage, no other significant ocular adverse events (AEs) were observed in either group during the12-month period. CONCLUSION: It is effective and cost-effective to treat DME by utilizing triamcinolone as an adjunct to the combination of anti-VEGF.http://ies.ijo.cn/en_publish/2021/6/20210612.pdfdiabetic macular edemaintravitreal triamcinoloneanti-vascular endothelial growth factor
collection DOAJ
language English
format Article
sources DOAJ
author Ying-Ying Yu
Yong Cheng
Li-Bin Chang
Hui-Ka Xia
Xiao-Xin Li
spellingShingle Ying-Ying Yu
Yong Cheng
Li-Bin Chang
Hui-Ka Xia
Xiao-Xin Li
Triamcinolone as an adjunct to the combination of anti-VEGF for the management of diabetic macular edema
International Journal of Ophthalmology
diabetic macular edema
intravitreal triamcinolone
anti-vascular endothelial growth factor
author_facet Ying-Ying Yu
Yong Cheng
Li-Bin Chang
Hui-Ka Xia
Xiao-Xin Li
author_sort Ying-Ying Yu
title Triamcinolone as an adjunct to the combination of anti-VEGF for the management of diabetic macular edema
title_short Triamcinolone as an adjunct to the combination of anti-VEGF for the management of diabetic macular edema
title_full Triamcinolone as an adjunct to the combination of anti-VEGF for the management of diabetic macular edema
title_fullStr Triamcinolone as an adjunct to the combination of anti-VEGF for the management of diabetic macular edema
title_full_unstemmed Triamcinolone as an adjunct to the combination of anti-VEGF for the management of diabetic macular edema
title_sort triamcinolone as an adjunct to the combination of anti-vegf for the management of diabetic macular edema
publisher Press of International Journal of Ophthalmology (IJO PRESS)
series International Journal of Ophthalmology
issn 2222-3959
2227-4898
publishDate 2021-06-01
description AIM: To assess the efficacy of intravitreal triamcinolone (IVTA) as an adjunct to the combination of anti-vascular endothelial growth factor (VEGF) for the management of diabetic macular edema (DME). METHODS: A total of 51 patients with visual disabilities causing by DME from two sites were retrospectively collected and assigned to two groups according to the therapeutic method: intravitreal conbercept (IVC) combined with focal laser (24 eyes) and IVC combined with focal laser and IVTA (27 eyes). Best-corrected visual acuity (BCVA), the required number of IVCs, central retinal thickness (CRT), the mean costs of treatment burden and safety were compared over 12mo. RESULTS: From baseline to month 1 through month 12, IVC combined with focal laser and IVTA improved the mean average change in BCVA superior to IVC combined with focal laser (+5.20 vs +2.71 letters). At month 12, 20.83% of the IVC combined with focal laser and 37.04% of IVC combined with focal laser and IVTA arms gained more than 10 BCVA letters. During the period, the mean CRT decreased significantly in the IVC combined with focal laser and IVTA arm (-245.9 μm) compared to the IVC combined with focal laser arm (-98.45 μm). The average of 6.45 and 1.25 conbercept injections performed in the IVC combined with focal laser and IVC combined with focal laser and IVTA arms, respectively. The mean cost of treatment burden for 12mo was $6247.44±4069.18 in the IVC combined with focal laser arm and $1679.19±542.73 in the IVC combined with focal laser and IVTA arm, with a statistically significant difference. Apart from occasional minor subconjunctival hemorrhage, no other significant ocular adverse events (AEs) were observed in either group during the12-month period. CONCLUSION: It is effective and cost-effective to treat DME by utilizing triamcinolone as an adjunct to the combination of anti-VEGF.
topic diabetic macular edema
intravitreal triamcinolone
anti-vascular endothelial growth factor
url http://ies.ijo.cn/en_publish/2021/6/20210612.pdf
work_keys_str_mv AT yingyingyu triamcinoloneasanadjuncttothecombinationofantivegfforthemanagementofdiabeticmacularedema
AT yongcheng triamcinoloneasanadjuncttothecombinationofantivegfforthemanagementofdiabeticmacularedema
AT libinchang triamcinoloneasanadjuncttothecombinationofantivegfforthemanagementofdiabeticmacularedema
AT huikaxia triamcinoloneasanadjuncttothecombinationofantivegfforthemanagementofdiabeticmacularedema
AT xiaoxinli triamcinoloneasanadjuncttothecombinationofantivegfforthemanagementofdiabeticmacularedema
_version_ 1721428133263966208